Prognostic significance of delayed complete metabolic response on PET/CT after primary chemoradiation treatment of cervical cancer

被引:0
作者
Michaan, Nadav [1 ,6 ]
Wenkert, Atalia [2 ]
Even-Sapir, Einat [3 ]
Kerzhner, Kosta [3 ]
Rabin, Tatiana [4 ]
Safra, Tamar [5 ]
Peleg-Hasson, Shira [5 ]
Baruch, Yoav [1 ]
Raz, Yael [1 ]
Grisaru, Dan [1 ]
Laskov, Ido [1 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Gynecol Oncol, Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Dept Obstet & Gynecol, Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Dept Nucl Med, Tel Aviv, Israel
[4] Tel Aviv Sourasky Med Ctr, Dept Radiat Oncol, Tel Aviv, Israel
[5] Tel Aviv Sourasky Med Ctr, Dept Oncol, Tel Aviv, Israel
[6] Tel Aviv Sourasky Med Ctr, Dept Gynecol oncol, IL-64239 Tel Aviv, Israel
关键词
Cervical Cancer; Genital Neoplasms; Female; Radiation Oncology; POSITRON-EMISSION-TOMOGRAPHY; QUALITY-OF-LIFE; THERAPY RESPONSE; CHEMORADIOTHERAPY; CARCINOMA; IMPACT; HEAD;
D O I
10.1136/ijgc-2023-004703
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective To investigate the prognostic significance of near-complete metabolic response on initial follow-up PET/CT after primary chemoradiation treatment of cervical cancer.Methods Survival data were retrospectively compared between patients who had complete metabolic response on first follow-up PET/CT, 3 months after chemoradiation (group 1) with those who had near-complete metabolic response on first PET/CT and later showed complete metabolic response at subsequent PET/CT, 6 months or more after treatment (group 2).Results Of the 108 patients included in the final analysis, 74 (68.5%) showed complete metabolic response on initial PET/CT, 3 months after treatment, and 34 patients (31.5%) showed complete metabolic response on subsequent PET/CT, 6 months after treatment. Tumor characteristics were comparable between groups. Group 1 had higher percent of stage 1 (12% vs 0%) and lower percent of stage 4 disease (3% vs 14%) than those of group 2. Group 2 patients had significantly fewer cases of recurrences and deaths than group 1 patients (6% vs 26%, p=0.018; 0% vs 20%, p=0.003, respectively), with comparable 3-year survival rates (group 1, 90% vs group 2, 100%, p=0.31). Twelve patients had progressive disease on first follow-up PET/CT; these patients had significantly worse overall survival compared with all other patients (log-rank test, p<0.001). Younger age and delayed complete metabolic response were associated with lower chance of recurrence and death on univariate analysis. On multivariate analysis, delayed complete metabolic response remained significantly associated with no recurrence HR=0.14 (95% CI 0.25 to 0.84), p=0.031.Conclusions Survival outcome of patients with cervical cancer who show residual 18F-fluorodeoxyglucose uptake on initial PET/CT after treatment, but reach complete metabolic response on follow-up PET/CT, is not inferior compared with survival of patients who show complete metabolic response on initial PET/CT 3 months after treatment. Watchful waiting with follow-up PET/CT seems a safe option for these patients.
引用
收藏
页码:1695 / 1701
页数:7
相关论文
共 21 条
  • [1] FDG PET/CT in monitoring response to treatment in gynecological malignancies
    Amit, Amnon
    Person, Orit
    Keidar, Zohar
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2013, 25 (01) : 17 - 22
  • [2] cdc, USCS data visualizations
  • [3] ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023*
    Cibula, David
    Raspollini, Maria Rosaria
    Planchamp, Francois
    Centeno, Carlos
    Chargari, Cyrus
    Felix, Ana
    Fischerova, Daniela
    Jahnn-Kuch, Daniela
    Joly, Florence
    Kohler, Christhardt
    Lax, Sigurd
    Lorusso, Domenica
    Mahantshetty, Umesh
    Mathevet, Patrice
    Naik, Raj
    Nout, Remi A.
    Oaknin, Ana
    Peccatori, Fedro
    Persson, Jan
    Querleu, Denis
    Bernabe, Sandra Rubio
    Schmid, Maximilian P.
    Stepanyan, Artem
    Svintsitskyi, Valentyn
    Tamussino, Karl
    Zapardiel, Ignacio
    Lindegaard, Jacob
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (05) : 649 - 666
  • [4] Cervical cancer
    Cohen, Paul A.
    Jhingran, Anjua
    Oaknin, Ana
    Denny, Lynette
    [J]. LANCET, 2019, 393 (10167) : 169 - 182
  • [5] Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial
    Glynne-Jones, Robert
    Sebag-Montefiore, David
    Meadows, Helen M.
    Cunningham, David
    Begum, Rubina
    Adab, Fawzi
    Benstead, Kim
    Harte, Robert J.
    Stewart, Jill
    Beare, Sandy
    Hackshaw, Allan
    Kadalayil, Latha
    [J]. LANCET ONCOLOGY, 2017, 18 (03) : 347 - 356
  • [6] The prognostic value of PET and PET/CT in cervical cancer
    Grigsby, Perry W.
    [J]. CANCER IMAGING, 2008, 8 (01): : 146 - 155
  • [7] Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix:: Response and outcome
    Grigsby, PW
    Siegel, BA
    Dehdashti, F
    Rader, J
    Zoberi, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2167 - 2171
  • [8] The impact of cervical cancer on quality of life - The components and means for management
    Herzog, Thomas J.
    Wright, Jason D.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 107 (03) : 572 - 577
  • [9] Use of Functional Magnetic Resonance Imaging in Cervical Cancer Patients With Incomplete Response on Positron Emission Tomography/Computed Tomography After Image-Based High-Dose-Rate Brachytherapy
    Kalash, Ronny
    Glaser, Scott M.
    Rangaswamy, Balasubramanya
    Horne, Zachary D.
    Kim, Hayeon
    Houser, Christopher
    Beriwal, Sushil
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (04): : 1008 - 1013
  • [10] Klugel S, 2017, INT J WOMENS HEALTH, V9, P795, DOI 10.2147/IJWH.S143368